Ultragenyx and Mereo BioPharma: What Analysts Are Saying After Trial Setbacks
Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.
Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.
Ultragenyx's setrusumab fails to reduce fractures in osteogenesis imperfecta patients in Phase 3 trials, though bone density improved. Company plans expense cuts.
JPMorgan is optimistic about Ultragenyx's drug setrusumab (UX143) and expects big gains ahead of key study updates.